Vimarsana
Biggest News Aggregation in the World

Page 6 - Durable Responses News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Durable Responses. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Durable Responses Today - Breaking & Trending Today

Novartis Pharma AG: FDA approves Novartis Scemblix (asciminib), with novel mechanism of action for the treatment of chronic myeloid leukemia - Vimarsana News

Novartis Pharma AG: FDA approves Novartis Scemblix (asciminib), with novel mechanism of action for the treatment of chronic myeloid leukemia

Scemblix provides much-needed and long-awaited new option for patients with chronic myeloid leukemia (CML) who suffer with intolerance or inadequate response after at least two previous tyrosine

Janssen Receives Positive CHMP Opinion for RYBREVANT (amivantamab) for the Treatment of Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations After Failure of Platinum-Based Therapy - Vimarsana News

Janssen Receives Positive CHMP Opinion for RYBREVANT (amivantamab) for the Treatment of Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations After Failure of Platinum-Based Therapy

If approved by the European Commission, amivantamab will be the first treatment in the European Union specifically targeting EGFR exon 20 insertion mutations for advanced non-small cell lung cancer